title: Pin1 modulates chemo-resistance by up-regulating FoxM1 and the involvements of Wnt/β-catenin signaling pathway in cervical cancer.
abstract: The prolyl isomerase Pin1, which is frequently highly expressed in many different cancers, can directly regulate cell proliferation and the cell cycle. However, the role of Pin1 in chemo-resistance remains to be elucidated in cervical cancer. The purpose of the present study was to investigate the role of Pin1 in the chemo-resistance of cervical cancer. The cisplatin resistance was assessed using the MTT assay. Pin1, FoxM1, β-catenin, Cyclin D1, and c-myc expression levels were detected by RT-qPCR or Western blot. The results showed that Pin1 expression displayed a similar expression pattern with the resistance to cisplatin in five cervical cell lines. Knockdown of Pin1 significantly increased the sensitivity to cisplatin in HeLa cells, while Pin1 overexpression decreased the sensitivity to cisplatin in Me180 cells. Knockdown of Pin1 significantly down-regulated FoxM1 expression in HeLa cells, while Pin1 overexpression showed a contrary effect in Me180 cells. Besides, overexpression of Pin1 markedly increased the protein expression of β-catenin and its target genes cyclin D1 and c-myc. FoxM1 siRNA remarkably reversed the promotory effect of pcDNA-Pin1(+) on β-catenin and its target genes cyclin D1 and c-myc in Me180 cells. Furthermore, we also found that FoxM1 siRNA and IWP-2 markedly decreased cell viability, and IWP-2 decreased cell viability to the maximum extent in the Me180 cells co-transfected with pcDNA-Pin1(+) and FoxM1 siRNA. Taken together, these data suggest that Pin1 contributes to cisplatin resistance, partly by up-regulating FoxM1 and Wnt/β-catenin signaling pathway involved in cervical cancer.
authors.affiliation: Department of Radiaton Oncology, First Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. twangrad@163.com.
authors.forename: Tao
authors.initials: T
authors.lastname: Wang
authors.affiliation: Department of Radiaton Oncology, First Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
authors.forename: Zi
authors.initials: Z
authors.lastname: Liu
authors.affiliation: Department of Radiaton Oncology, First Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
authors.forename: Fan
authors.initials: F
authors.lastname: Shi
authors.affiliation: Department of Radiaton Oncology, First Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
authors.forename: Jiquan
authors.initials: J
authors.lastname: Wang
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm; D005260:Female; D000072278:Forkhead Box Protein M1; D051858:Forkhead Transcription Factors / Q000235:genetics / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006367:HeLa Cells; D006801:Humans; D000072340:NIMA-Interacting Peptidylprolyl Isomerase; D019696:Peptidylprolyl Isomerase / Q000235:genetics* / Q000378:metabolism; D015854:Up-Regulation; D002583:Uterine Cervical Neoplasms / Q000235:genetics* / Q000378:metabolism; D060449:Wnt Signaling Pathway / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; C107585:FOXM1 protein, human; D000072278:Forkhead Box Protein M1; D051858:Forkhead Transcription Factors; D000072340:NIMA-Interacting Peptidylprolyl Isomerase; C000606846:PIN1 protein, human; D019696:Peptidylprolyl Isomerase; D002945:Cisplatin
keywords: Cervical cancer; Chemo-resistance; Cisplatin; FoxM1; Pin1
references.citation: Cancer Res. 2003 Oct 1;63(19):6244-51
references.pmid: 14559810
references.citation: Am J Pathol. 2004 May;164(5):1727-37
references.pmid: 15111319
references.citation: Nat Rev Cancer. 2007 Nov;7(11):847-59
references.pmid: 17943136
references.citation: Clin Cancer Res. 2005 Oct 15;11(20):7523-31
references.pmid: 16243827
references.citation: Neoplasma. 2015 ;62(1):61-71
references.pmid: 25563368
references.citation: World J Gastroenterol. 2005 Aug 28;11(32):5006-9
references.pmid: 16124054
references.citation: Nat Rev Cancer. 2003 Jul;3(7):502-16
references.pmid: 12835670
references.citation: Cell Signal. 2008 Nov;20(11):1921-6
references.pmid: 18555662
references.citation: Curr Pharm Des. 2012;18(17):2464-71
references.pmid: 22372504
references.citation: Oncogene. 2004 May 20;23 (23 ):4182-6
references.pmid: 15064734
references.citation: Gynecol Oncol. 2013 Dec;131(3):772-9
references.pmid: 24125749
references.citation: Oncol Rep. 2009 Apr;21(4):1097-104
references.pmid: 19288014
references.citation: Mol Cancer Res. 2010 Jan;8(1):24-34
references.pmid: 20068070
references.citation: Oncogene. 2012 Apr 12;31(15):1869-83
references.pmid: 21892204
references.citation: Ann Surg Oncol. 2013 Mar;20(3):1035-43
references.pmid: 23054116
references.citation: Cancer Biol Ther. 2010 Jan;9(2):111-9
references.pmid: 20009523
references.citation: Nat Rev Drug Discov. 2014 Jul;13(7):513-32
references.pmid: 24981364
references.citation: Biochim Biophys Acta. 2012 Jan;1819(1):28-37
references.pmid: 21978825
references.citation: Oncol Rep. 2003 Jul-Aug;10 (4):1045-8
references.pmid: 12792768
references.citation: Cancer Res. 2008 Aug 1;68(15):6109-17
references.pmid: 18676833
references.citation: Nat Rev Cancer. 2008 Mar;8(3):242
references.pmid: 18297052
references.citation: Mol Carcinog. 2006 Jun;45(6):397-402
references.pmid: 16652378
references.citation: Cancer J. 2011 Mar-Apr;17(2):89-95
references.pmid: 21427552
references.citation: Cancer Cell. 2011 Oct 18;20(4):427-42
references.pmid: 22014570
references.citation: Oncol Rep. 2006 Sep;16(3):491-6
references.pmid: 16865248
references.citation: Cell Res. 2014 Sep;24(9):1033-49
references.pmid: 25124924
references.citation: J Pathol. 2004 Apr;202(4):446-55
references.pmid: 15095272
references.citation: Expert Opin Ther Targets. 2011 Jul;15(7):873-87
references.pmid: 21486121
references.citation: Cold Spring Harb Perspect Biol. 2012 May 01;4(5):null
references.pmid: 22438566
references.citation: Lung Cancer. 2013 Feb;79(2):173-9
references.pmid: 23177020
references.citation: Oncogene. 2016 Apr 28;35(17 ):2166-77
references.pmid: 26279295
references.citation: J Cell Sci. 2003 Mar 1;116(Pt 5):773-83
references.pmid: 12571275
references.citation: PLoS One. 2014 May 13;9(5):e96989
references.pmid: 24824601
references.citation: Pharmacol Rev. 2012 Jul;64(3):706-21
references.pmid: 22659329
references.citation: Biochim Biophys Acta. 2007 Jan;1775(1):92-102
references.pmid: 17014965